Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
1996

HER-2/neu Signalling in Breast Cancer

Sample size: 223 publication Evidence: moderate

Author Information

Author(s): MP DiGiovanna, D Carter, SD Flynn, DF Stern

Primary Institution: Yale University School of Medicine

Hypothesis

The variability in the prognostic ability of HER-2/neu overexpression may be due to active signalling in a subset of tumours.

Conclusion

HER-2/neu is phosphorylated and actively signalling in only a minority of invasive breast carcinomas that overexpress this receptor.

Supporting Evidence

  • Overexpression of HER-2/neu was detected in 9% of 223 cases.
  • Active signalling by HER-2/neu was detected in only 35% of the overexpressing cases.
  • Phosphorylated HER-2/neu was associated with a lower rate of progesterone receptor positivity.

Takeaway

Some breast cancer tumors have a protein called HER-2/neu that can be active or inactive. Only a few of the tumors with high levels of this protein are actually active.

Methodology

The study involved immunohistochemical staining of 262 cases of invasive breast carcinomas, with 223 cases analyzed after excluding those without invasive carcinoma.

Limitations

The study's findings may be limited by the sensitivity of the antibodies used for detecting HER-2/neu.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication